REVIEW ON ISCHEMIC HEART DISEASES AND ITS MEDICATION
ABOUT AUTHORS
Salman S. Dhankwala*, Ajinkya N. Gavsane, Prithvirj M. Ghuli, Sagar A. Jadhav
Department of Pharmaceutical Chemistry,
Appasaheb Birnale College of Pharmacy,
Sangli, Maharashtra, India
*salman.2.dhankwala@gmail.com
{ DOWNLOAD AS PDF }
ABSTRACT
Ischemic heart diseases are a major public health problem, it includes disorders of the heart and blood vessel. Ischemia is a condition in which the blood flow (and thus oxygen) is restricted or reduced in a part of the body.Cardiac ischemia is the name for decreased blood flow and oxygen to the heart muscle It's the term given to heart problems caused by narrowed heart arteries. When arteries are narrowed, less blood and oxygen reaches the heart muscle. This is also called coronary artery disease and coronary heart disease. This can ultimately lead to attack. Ischemia often causes chest pain or discomfort known as angina pectoris. Disease is diagnosed according to medical parameters; following diagnosis of the disease the treatment is started. The treatment is includes in medicines of Heart diseases and is as well as lifestyle.

At Universal Sompo General Insurance Co. Ltd, we believe relationships with our stakeholders is strengthened & nurtured by imbibing an attitude towards ‘Caring’ and a commitment of ‘Concern’ towards the welfare of our customers and employees during the time of distress, as well as, being preemptive towards mitigating future Risks. Our Customer Outreach activities include organizing Health Camps and Consumer Awareness Roadshows for providing knowledge empowerment and overall wellbeing of our customers. We stand-by our customers and citizens of our country during natural catastrophic events and give our best efforts to try and minimize their distressful situations through our team efforts and leveraging our network channels for extending assistance services. At workplace, we work towards creating a healthy work environment for our fellow colleagues through organizing internal Employee Engagement activities towards Training, Employee Welfare and fun activities during the festive period and important national celebrations. Let us give you a glimpse of our universe.
Clinical Development Services Agency (CDSA) is an extramural unit of Translational Health Science and Technology Institute which is an autonomous institute created by the Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India to strengthen the existing clinical trial / study capacity for affordable health care products in India and raise it to international standards. It is committed to strengthening and expanding the evidence base for healthcare nationally. CDSA has a national reputation for assisting academic investigators, bio-pharma entrepreneurs and innovative SMEs in the delivery of clinical trials and cohort studies throughout their life cycle from set up to closure. Over time, and building on current strengths, the mission of the Clinical Portfolio Section of CDSA is to become a centre of excellence that supports the conduct of Phase III/IV clinical trials and epidemiological studies of national importance.
Center of Innovative and Applied Bioprocessing (CIAB) is an autonomous national institute under Department of Biotechnology (Govt. of India). This futuristic innovation institute of its own kind in the country has a mission of advancing knowledge, leads and emerging technologies/processes relevant to agri-food sector towards applications and products. It aims to link them with societal benefits through catalysing/promoting entrepreneurial action around bioprocesses, bio-products, value-addition to bioproducts etc. with special reference to the agrifood sector. Currently, the four major mandated R&D areas in hand at the institute are (A) Value Addition to Primary Processing Residues/ Wastes for Edible Products; (B) Valorisation of Crop Waste for Speciality Products and Chemicals; (C) Nutritionals, nutraceuticals and upgradation of value or use of bio-products, (D) Biosynthetic technology/synthetic biology for low volume-high value products and industrial enzymes. To support and steer this mission, the institute requires following temporary research positions on stipendary / fellowship basis:
The Institute of Chemical Technology (ICT) Mumbai was established as the Department of Chemical Technology on 1st October, 1933 by the University of Mumbai, through active support of industries and philanthropists. The Institute was most popularly known as UDCT, Mumbai. Research has been an integral part of ICT since its inception and it has created over 500 first generation entrepreneurs. The UDCT grew significantly in stature and was granted autonomy under UGC regulations by the University of Mumbai and further converted in to an Institute on 26th January, 2002. Under the World Bank TEQIP programme, the Maharashtra government granted it full autonomy in June 2004. Due to the recommendations of the Government of Maharashtra and University of Mumbai, the ICT was granted Deemed University Status by the MHRD on 12th September, 2008, with all provisions of the UGC for funding and support as the state owned deemed university.
Panacea Biotec is a leading research based Health Management Company, with an annual turnover of approx. Rs. 830 Crores. We are engaged in research, development, manufacture & marketing of Vaccines, Bio-Pharmaceuticals and Pharmaceuticals (Rx & OTC) of international quality and Health Services. All Panacea Biotec plants are accredited by international agencies and they follow current Good Manufacturing Practices, as per WHO guidelines.

